Next Post

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

[ad_1] CRISPR Therapeutics AG – More than 75 patients dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; planned global regulatory submissions on track for late 2022- -Initiated two new CTX001 Phase 3 clinical trials in pediatric patients with TDT and SCD- -Enrollment and dosing ongoing for CTX110™, targeting CD19+ […]